摘要
The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios （OR） and corresponding 95% confidence intervals （CIs） were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models （GG vs. TT： OR, 1.123; 95% CI, 1.056--1.193; GG/GT vs. TT： OR, 1.028; 95% CI, 1.006--1.050）. In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital-/population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer （GG vs. TT： OR, 0.606; 95% CI, 0.407-0.903; GG/GT vs. TT： OR, 0.748; 95% CI, 0.579--0.968）. In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios （OR） and corresponding 95% confidence intervals （CIs） were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models （GG vs. TT： OR, 1.123; 95% CI, 1.056--1.193; GG/GT vs. TT： OR, 1.028; 95% CI, 1.006--1.050）. In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital-/population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer （GG vs. TT： OR, 0.606; 95% CI, 0.407-0.903; GG/GT vs. TT： OR, 0.748; 95% CI, 0.579--0.968）. In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
基金
supported by the National Basic Research Program of China(No.2010CB534901)
the National Natural Science Foundation of China(Nos.81000906,30771198 and 30971583)
the Natural Science Foundation of Heilonjiang Province,China(No.ZJY0702)
